Coronado Biosciences, Inc. (NASDAQ:CNDO)

CAPS Rating: 2 out of 5

Results 1 - 9 of 9

Recs

0
Member Avatar marsuculix (46.12) Submitted: 3/23/2015 6:08:17 AM : Underperform Start Price: $3.75 CNDO Score: -4.56

looks better than it is...

Recs

0
Member Avatar Bioguy65 (90.00) Submitted: 3/14/2015 10:18:29 AM : Underperform Start Price: $3.37 CNDO Score: -16.14

I learned a lot about CNDO when I was heavily long betting on the TSO trials for Crohn's. Having lost badly, I am more pessimistic especially in light of the fact that the old CNDO was headed by superstar CEO Harlan Weisman, who guided Remicade to market. If I recollect correctly, he left after the Crohn's failure (likely forced out) and Lindsey Rosenwald brought in his business partner Weiss to CNDO (Weiss is also CEO of TGTX), and they granted themselves an enormous amount of CNDO stock options with vesting contingent on performance. They have just collaborated with CNDO teaming with TGTX and mentioning the magic phrase CAR-T, and poof, artificial value is created in CNDO. I am not interested enough to even look to see if the increase in PPS of CNDO triggers the contingent options that Rosenwald and Weiss conspired to take from CNDO shareholders when they granted themselves the options in the first instance. Either way, this has scam written all over it.

Recs

2
Member Avatar zzlangerhans (99.81) Submitted: 3/5/2015 12:55:37 AM : Outperform Start Price: $3.30 CNDO Score: +18.51

As I write, it seems like the saga of Pharmacyclics has come to an end with a share price more than 100 fold higher than the lows in 2009. I was certainly a skeptic, but fortunately for my brokerage account and my CAPS score I turned it around before it was too late. What made Pharmacyclics such a sleeper? It was the persistence of the company in wasting remaining resources on Xyctrin after it was obvious to everyone that it was a failure, coupled with the spec crash that seemed as though it would wipe out dozens of biotech stocks. No one was really watching as management underwent a hostile takeover and a new anti-cancer compound advanced into clinical trials. That compound became Imbruvica and the rest is history. I learned from Pharmacyclics not to dismiss a company until I was sure there was nothing of value left in the pipe.

Coronado isn't a close parallel to Pharmacyclics, but I do think there are few eyes on the company right now as they reinvent themselves following the predictable failure of worm eggs to cure autoimmune diseases. After bottoming below 1.5 last year, the company has been restructuring themselves in a complex way. A new subsidiary called CB Acquisition Group was funded with a small IPO and will apparently be spun off. This morning Coronado announced the formation of another subsidiary to be called Checkpoint Therapeutics. Checkpoint will advance a portfolio of human IO-targeted mAb's developed by Wayne Marasco at Dana Farber. Checkpoint has collaborated with TG Therapeutics to develop the anti-PD-L1 and anti-GTR Ab programs in hematologic malignancies. TG Therapeutics is connected to Lindsay Rosenwald, the CEO of Coronado and a long-term player in biopharma venture financing.

What does all this mean? I think Rosenwald has bigger fish to fry than just dragging out his lifespan as CEO of Coronado. That salary is pocket change for him. There's clearly an attempt here to become a serious player in the IO field, which is one of the hottest areas in oncology. If they can pull it off, Coronado will be worth a lot more than the 150M cap they sport today. I made a rapid decision to buy 2000 shares in the premarket at 3.05 this morning and wished I had gone ahead with 20000 as the share price shot up over 3.6. In the end, I held my shares as the stock settled at 3.2 and I imagine the position will get substantially larger if the near-term price action doesn't indicate that I've been suckered.

Recs

0
Member Avatar OklaBoston (64.13) Submitted: 1/15/2015 10:46:52 AM : Outperform Start Price: $2.40 CNDO Score: +57.53

Former $13 stock appears to have bottomed out.

Also has high and up-trended insider ownership.

Recs

0
Member Avatar JavaChipFool (49.51) Submitted: 2/5/2014 3:22:21 PM : Outperform Start Price: $2.45 CNDO Score: +39.42

Biotech gamble, down but not out

Recs

0
Member Avatar fatmoneyrz (99.24) Submitted: 10/14/2013 2:19:27 PM : Outperform Start Price: $2.10 CNDO Score: +62.44

Nice entry on nice little biotech with a solid pipeline and solid cash position.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:30:28 PM : Underperform Start Price: $10.02 CNDO Score: +83.59

Biotech. Big losses. Selling tons of stock.

Recs

0
Member Avatar dwhit110 (< 20) Submitted: 7/15/2013 12:22:21 PM : Outperform Start Price: $8.63 CNDO Score: -78.13

The company has a smart and experienced executive team with past pharma experiencing getting drugs from the trial to FDA approved stage.

It's all a question of if their innovative solutions work as they're supposed to.

Recs

1
Member Avatar jcarnoldsf (27.65) Submitted: 1/25/2012 6:12:22 PM : Outperform Start Price: $6.18 CNDO Score: -98.76

This young biotech has a top-notch management team and an exciting roster of drugs entering final stage testing. The drugs are targeting autoimmune diseases and cancer. The most novel is an approach using parasites to activate the immune system. Has potential to be a big winner - buy now while it's still cheap!

Results 1 - 9 of 9

Featured Broker Partners


Advertisement